Last reviewed · How we verify
Pre-emptive mycophenolate
Mycophenolate works by inhibiting inosine monophosphate dehydrogenase, an enzyme crucial for the synthesis of guanosine nucleotides, thereby suppressing lymphocyte proliferation.
Mycophenolate works by inhibiting inosine monophosphate dehydrogenase, an enzyme crucial for the synthesis of guanosine nucleotides, thereby suppressing lymphocyte proliferation. Used for Prevention of organ rejection in kidney transplant patients, Treatment of certain autoimmune diseases, such as lupus nephritis.
At a glance
| Generic name | Pre-emptive mycophenolate |
|---|---|
| Sponsor | University of Bologna |
| Drug class | Immunosuppressant |
| Target | Inosine monophosphate dehydrogenase |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This action results in a decrease in the production of lymphocytes, which are a type of white blood cell involved in the immune response. By reducing the number of lymphocytes, mycophenolate helps to prevent the body from rejecting transplanted organs. Additionally, its immunosuppressive effects can also help to reduce inflammation and prevent autoimmune diseases.
Approved indications
- Prevention of organ rejection in kidney transplant patients
- Treatment of certain autoimmune diseases, such as lupus nephritis
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Abdominal pain
- Leukopenia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pre-emptive mycophenolate CI brief — competitive landscape report
- Pre-emptive mycophenolate updates RSS · CI watch RSS
- University of Bologna portfolio CI